When: Daily close below $25.50 (200 SMA break)

Then: Escalate to Sell reassessment

When: Post-Q3 earnings (late October) if structural FCF recovery confirmed and dividend reaffirmed

Then: Reassess rating and sizing

SELL (direction endorsed but execution must be tightened—either trim 40-50% or hedge remaining position with puts/collar)

• Endorses SELL direction but considers 25-30% trim insufficient; argues 70-75% long exposure into binary Q3 catalyst is reduced-aggressive, not conservative
• PEG ratio of 12.56 shows market is not paying for growth; rising moving averages reflect post-COVID normalization and Seagen integration narrative, not secular growth
• Trailing PE of 36x reflects GAAP earnings gutted by impairments, not genuine earnings power
• $4.3 billion Q2 asset writedown and $4.0 billion in special charges distort underlying earnings picture
• 1.3x FCF coverage on $9.8 billion annual dividend is structurally fragile; Q2 FCF collapsed to $302 million while $2.45 billion in dividends went out
• Short-term momentum deterioration: 7 sessions below 10 EMA, MACD histogram negative for 4 sessions rolling over from +0.85 peak, RSI cooled from 77 to 52 without overshooting meaningfully
• Current $28.96 stop loss (upper Bollinger Band / September 2 high) is a re-entry signal, not a protective stop—requires stock to break resistance ceiling to trigger, which would mean bearish thesis failed
• Recommends tightening stop to ~$28.30 (above Bollinger midline) or eliminating pre-commit reload level entirely
• Binary Q3 risks include Ibrance franchise repricing after SERENA-4 failure, $62 billion revenue guide sustainability, and dividend survivability under FCF pressure
• Two-path framework: either trim 40-50% to genuinely reduce binary exposure, or hold smaller trim but explicitly hedge remainder into print with protective puts or collar

→ vs neutral: The 'constructive medium- and long-term trend' framing based on price above 50 SMA ($26.46) and 200 SMA ($25.60) is technically accurate but substantively misleading—rising MAs reflect post-COVID normalization off a depressed earnings base, not secular growth; the PEG ratio of 12.56 makes this explicit

→ vs neutral: Labeling deteriorating momentum (7 sessions below 10 EMA, MACD negative 4 sessions rolling over from +0.85, RSI 77→52 without overshoot) as 'healthy consolidation' is the exact framing that gets portfolios run over when distribution resolves to the downside

→ vs aggressive: 25-30% trim is directionally correct but insufficient in size—70-75% long exposure into a setup where the dividend question could move from theoretical to forced is not conservative positioning; the principle of reducing risk doesn't stop at 25% exposure

→ vs aggressive: The $28.96 stop loss is positioned at the upper Bollinger Band and September 2 high—exactly the resistance level; a stop that requires the stock to break above resistance to trigger means selling into strength and reloading at the level where the bearish thesis fails, which is momentum-chasing disguised as technical discipline

SELL with 25-30% trim to 70-75% remaining position; replace 28.96 stop with 28.30-28.50 zone; tranche execution

• 6.26% dividend yield on 0.30 beta name provides real portfolio defense, not a meme
• 95% Fed cut odds, 10% recession risk, oil around $100 support keeping defensive high-yield exposure
• Q2 FCF collapse to $302M was timing artifact ($3.5B tax payment + working capital), not structural failure
• 25-30% trim reduces binary event exposure by ~25% without overcommitting to Q3 outcome
• Stop at 28.96 (upper Bollinger Band) is functionally a reload trigger, not a stop—replace with 28.30-28.50
• Tranche execution: sell ~half at 27.60-27.80 weakness, hold rest for bounce to 28.30-28.50 reassessment level
• Do not buy protective puts on 0.30 beta name—the trim is the hedge; puts would cost a quarter of dividend income
• Post-Q3, reassess whether 70-75% base position is still correct on fresh data

→ vs aggressive: Yield of 6.26% on 0.30 beta name is real defensive value, not a meme; it provides ~6% total return even in flat price range over 12 months

→ vs aggressive: Opportunity cost argument is unverified—no superior risk-adjusted setup actually identified in a compressed ERP, narrowed breadth environment

→ vs conservative: 40-50% trim overcommits to bearish Q3 scenario when most likely outcome is messy but manageable print

→ vs conservative: Protective puts on 0.30 beta name with 6.26% yield will cost meaningful chunk of one quarter's dividend income